| Patient | Flannery O'Connor |
|---|---|
| Date of birth | 2001-03-25 |
| Identifiers | MRN HR-ML046-SYN; SSN (made up) 000-46-1853 |
| Document date | 2026-06-15 |
| Author | Augusta Pemberton-Diallo, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Burning on passing urine and going often for two days. [S]
Ms. O'Connor is a 25-year-old writer with systemic lupus erythematosus and class III lupus nephritis, seven weeks into treatment with mycophenolate 1000 mg twice daily, weekly belimumab, hydroxychloroquine, losartan, and prednisone, now 15 mg a day. For two days she has had burning on passing urine, frequency, urgency, and lower abdominal discomfort. She has no fever on her home thermometer, chills, back or flank pain, vomiting, vaginal discharge, or rash, and her joints are quiet. She has a levonorgestrel intrauterine system. She called because she had been told that any infection on her treatment should be seen the same day, and she wanted to know whether this was her kidneys. [S]
| Element | Detail |
|---|---|
| Onset | Two days ago |
| Location | Bladder; no flank pain |
| Duration | Two days |
| Character | Burning, frequency, urgency |
| Severity | Moderate; writing still |
| Context | Mycophenolate, belimumab, and prednisone 15 mg; intrauterine system |
| Modifying factors | Extra fluids help a little |
| Associated signs and symptoms | No fever, chills, flank pain, vomiting, or discharge |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever or chills |
| Genitourinary | Positive | Dysuria, frequency, urgency, suprapubic discomfort; no flank pain or discharge |
| Gastrointestinal | Negative | No vomiting or diarrhea |
| Musculoskeletal | Negative | No joint pain or swelling |
| Integumentary | Negative | No rash |
5 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Acetaminophen 500 mg oral tablet, two tablets (1000 mg) by mouth up to three times a day as needed for joint pain, no more than 3000 mg a day | Two tablets up to every 8 hours as needed | Oral route | 2026-04-13 | active | S |
| Hydroxychloroquine sulfate 300 mg oral tablet, one tablet by mouth once daily (5 mg/kg of actual body weight), long term | One tablet once daily | Oral route | 2026-04-22 | active | S |
| Losartan potassium 25 mg oral tablet, one tablet by mouth once daily, for proteinuria and blood pressure | One tablet once daily | Oral route | 2026-04-22 | active | S |
| Methylprednisolone 500 mg intravenous infusion once daily for three days | One infusion daily for three days | Intravenous route | 2026-04-29 to 2026-05-01 | completed | S |
| Prednisone 5 mg oral tablet: 30 mg (six tablets) once daily from the day after the last pulse, reduced by 5 mg every two weeks to 10 mg, then to 5 mg a day or less by six months | Once daily, tapering | Oral route | 2026-04-29 | active | S |
| Mycophenolate mofetil 500 mg oral tablet, one tablet twice daily for one week, then two tablets (1000 mg) twice daily | Two tablets twice daily | Oral route | 2026-04-29 | active | S |
| Belimumab 200 mg/mL subcutaneous autoinjector: 400 mg (two injections) once weekly for four doses, then 200 mg once weekly | Once weekly by self-injection | Subcutaneous route | 2026-04-29 | active | S |
| Cholecalciferol (vitamin D3) 1000 units oral tablet, one tablet by mouth once daily | One tablet once daily | Oral route | 2026-04-29 | active | S |
| Nitrofurantoin (monohydrate/macrocrystals) 100 mg oral capsule, one capsule by mouth twice daily with food for seven days | One capsule twice daily for seven days | Oral route | 2026-06-15 to 2026-06-21 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-06-15 | Body height | 168 | cm | S |
| 2026-06-15 | Body weight | 62.4 | kg | S |
| 2026-06-15 | Body mass index (BMI) [Ratio] | 22.1 | kg/m2 | S |
| 2026-06-15 | Systolic blood pressure | 124 | mm[Hg] | S |
| 2026-06-15 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 2026-06-15 | Heart rate | 84 | /min | S |
| 2026-06-15 | Respiratory rate | 14 | /min | S |
| 2026-06-15 | Body temperature | 37.3 | Cel | S |
| 2026-06-15 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-06-15 | Leukocytes [#/volume] in Blood by Automated count | 7.9 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-06-15 | Creatinine [Mass/volume] in Serum or Plasma | 0.8 | mg/dL | 0.5-1.1 mg/dL | Normal | S |
| 2026-06-15 | Potassium [Moles/volume] in Serum or Plasma | 4.6 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
Vital signs recorded on 2026-06-15; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well-appearing; temperature 37.3 °C, pulse 84/min |
| Abdomen | Mild suprapubic tenderness; no masses |
| Back | No costovertebral angle tenderness |
| Skin | No malar rash; no lesions |
| Musculoskeletal | No joint swelling or tenderness |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Pain and swelling of the small joints of both hands, the wrists, and the knees for three months, with an hour of morning stiffness, evening fevers to 38 °C, fatigue, and a red rash over the cheeks and nose after sun; told elsewhere it might be rheumatoid arthritis; cause to be established | resolved | confirmed | M25.50 | S — Synthetic presenting concern at the index visit, superseded by the diagnosis of systemic lupus erythematosus at the second visit; joint pain in 1950 with suspected rheumatoid arthritis is documented (D). |
| Protein and blood in the urine: protein-to-creatinine ratio 1.6 g/g and 18 red cells per high-power field, with normal creatinine; cause to be established | resolved | confirmed | R80.9 | S — Synthetic presenting finding at the index visit, superseded by the kidney biopsy diagnosis at the third visit. |
| Systemic lupus erythematosus, classified by the EULAR/ACR criteria (ANA 1:640 homogeneous; score 32 before the biopsy): inflammatory arthritis, acute cutaneous lupus (malar rash), fever, leukopenia with lymphopenia, mild thrombocytopenia, low C3 and C4, anti-dsDNA and anti-Sm positive; antiphospholipid antibodies and lupus anticoagulant negative | active | confirmed | M32.19 | S — Synthetic modern diagnosis and results; her systemic lupus erythematosus, diagnosed in Atlanta in late 1950 or early 1951, is documented (D), but no finding from her lifetime is used. |
| Lupus nephritis, ISN/RPS class III (A), focal proliferative, on kidney biopsy: endocapillary proliferation in 9 of 30 glomeruli, activity index 6 of 24, chronicity index 1 of 12, full-house immunofluorescence; no thrombotic microangiopathy; urine protein-to-creatinine ratio 1.8 g/g; normal kidney function | active | confirmed | M32.14 | S — Synthetic biopsy result and class; kidney involvement is documented at the end of her life, but no kidney finding from her lifetime is used. |
| Long-term glucocorticoid treatment for lupus nephritis, tapering to 5 mg a day or less | active | confirmed | Z79.52 | S — Synthetic treatment status; the documented steroid harm in her life is the reason the episode keeps glucocorticoids low. |
| Long-term mycophenolate mofetil, with belimumab, for lupus nephritis; bone and infection protection in place | active | confirmed | Z79.624 | S — Synthetic treatment status. |
| Levonorgestrel intrauterine system for highly effective contraception during mycophenolate treatment | active | confirmed | Z97.5 | S — Synthetic contraception, chosen by the patient. |
| Acute cystitis on mycophenolate, belimumab, and prednisone 15 mg: two days of burning, frequency, and urgency without fever or flank pain; urine culture grew Escherichia coli sensitive to nitrofurantoin; resolved with seven days of nitrofurantoin | resolved | confirmed | N30.00 | S — Synthetic common infection in an immunosuppressed young woman; coded without hematuria because the persistent hematuria is from her nephritis. |
Guideline basis: EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis 2024;83(1):15-29 (2023); 2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis. Arthritis Rheumatol 2025;77(9):1115-1135 (2024); International Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women: A 2010 Update by the IDSA and ESCMID. Clin Infect Dis 2011;52(5):e103-e120 (2010)
Follow-up: Culture result by telephone in two days. Rheumatology blood count as scheduled. Three-month review in six weeks. Next scheduled visit 2026-07-27: three-month response assessment for lupus nephritis and glucocorticoid taper. [S]